117 related articles for article (PubMed ID: 1348351)
1. Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of parkinsonism.
Gomez-Mancilla B; Boucher R; Bédard PJ
Mov Disord; 1992; 7(1):43-7. PubMed ID: 1348351
[TBL] [Abstract][Full Text] [Related]
2. Effect of ethosuximide on rest tremor in the MPTP monkey model.
Gomez-Mancilla B; Latulippe JF; Boucher R; Bédard PJ
Mov Disord; 1992; 7(2):137-41. PubMed ID: 1350061
[TBL] [Abstract][Full Text] [Related]
3. Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors.
Gomez-Mancilla B; Boucher R; Gagnon C; Di Paolo T; Markstein R; Bédard PJ
Mov Disord; 1993 Apr; 8(2):144-50. PubMed ID: 8474480
[TBL] [Abstract][Full Text] [Related]
4. Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys.
Gomez-Mancilla B; Bédard PJ
J Pharmacol Exp Ther; 1991 Oct; 259(1):409-13. PubMed ID: 1681090
[TBL] [Abstract][Full Text] [Related]
5. Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease.
Temlett JA; Quinn NP; Jenner PG; Marsden CD; Pourcher E; Bonnet AM; Agid Y; Markstein R; Lataste X
Mov Disord; 1989; 4(3):261-5. PubMed ID: 2571082
[TBL] [Abstract][Full Text] [Related]
6. The effects of D1 and D2 dopamine receptor agonist and antagonist on parkinsonism in chronic MPTP-treated monkeys.
Nomoto M; Fukuda T
Adv Neurol; 1993; 60():119-22. PubMed ID: 8093574
[No Abstract] [Full Text] [Related]
7. Antiparkinsonian effects of BAM-1110, a novel ergoline derivative, in MPTP-treated cynomolgus monkeys.
Kuno S; Mizuta E; Sakamoto H; Ichihara K; Nagasaka M
Clin Neuropharmacol; 1998; 21(1):35-40. PubMed ID: 9579283
[TBL] [Abstract][Full Text] [Related]
8. The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset.
Nomoto M; Jenner P; Marsden CD
Neurosci Lett; 1985 Jun; 57(1):37-41. PubMed ID: 3162113
[TBL] [Abstract][Full Text] [Related]
9. Effects of a selective partial D1 agonist, CY 208-243, in de novo patients with Parkinson disease.
Emre M; Rinne UK; Rascol A; Lees A; Agid Y; Lataste X
Mov Disord; 1992; 7(3):239-43. PubMed ID: 1535688
[TBL] [Abstract][Full Text] [Related]
10. Effect of clonidine and atropine on rest tremor in the MPTP monkey model of parkinsonism.
Gomez-Mancilla B; Boucher R; Bédard PJ
Clin Neuropharmacol; 1991 Aug; 14(4):359-66. PubMed ID: 1913702
[TBL] [Abstract][Full Text] [Related]
11. No direct correlation between behaviorally active doses of the dopamine D2 agonist LY 171555 and displacement of [123I]IBZM as measured with SPECT in MPTP monkeys.
Vermeulen RJ; Drukarch B; Verhoeff NP; Goosen C; Sahadat MC; Wolters EC; van Royen EA; Stoof JC
Synapse; 1994 Jun; 17(2):115-24. PubMed ID: 7916490
[TBL] [Abstract][Full Text] [Related]
12. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
Pearce RK; Jackson M; Smith L; Jenner P; Marsden CD
Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
[TBL] [Abstract][Full Text] [Related]
13. D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys.
Goulet M; Madras BK
J Pharmacol Exp Ther; 2000 Feb; 292(2):714-24. PubMed ID: 10640310
[TBL] [Abstract][Full Text] [Related]
14. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
[TBL] [Abstract][Full Text] [Related]
15. Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys.
Bédard PJ; Gomez-Mancilla B; Blanchette P; Gagnon C; Falardeau P; DiPaolo T
Adv Neurol; 1993; 60():113-8. PubMed ID: 8093573
[No Abstract] [Full Text] [Related]
16. Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset.
Nomoto M; Stahl S; Jenner P; Marsden CD
Mov Disord; 1987; 2(1):37-45. PubMed ID: 2904119
[TBL] [Abstract][Full Text] [Related]
17. Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys.
Gomez-Mancilla B; Bédard PJ
Exp Neurol; 1992 Aug; 117(2):185-8. PubMed ID: 1354166
[TBL] [Abstract][Full Text] [Related]
18. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets.
Smith L; De Salvia M; Jenner P; Marsden CD
Mov Disord; 1996 Mar; 11(2):125-35. PubMed ID: 8684381
[TBL] [Abstract][Full Text] [Related]
19. Effects of terguride, a partial D2 agonist, on MPTP-lesioned parkinsonian cynomolgus monkeys.
Akai T; Yamaguchi M; Mizuta E; Kuno S
Ann Neurol; 1993 May; 33(5):507-11. PubMed ID: 8098931
[TBL] [Abstract][Full Text] [Related]
20. MPTP-induced parkinsonism in the common marmoset: behavioral and biochemical effects.
Jenner P; Rose S; Nomoto M; Marsden CD
Adv Neurol; 1987; 45():183-6. PubMed ID: 2881443
[No Abstract] [Full Text] [Related]
[Next] [New Search]